Please login to the form below

Not currently logged in
Email:
Password:

Dextroamphetamine

This page shows the latest Dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

Shire weathers generic Adderall XR challenge

dextroamphetamine). Authorised generics of Adderall XR sold by Teva and Impax, for which Shire receives a percentage of sales, have been available since 2009, but in June 2012, Actavis launched its

Latest news

  • FDA issues counterfeit Adderall warning

    Legitimate versions of Adderall should contain dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate.

  • Shire's once-daily ADHD drug Venvanse accepted for European review

    In addition to Venvanse, Shire's ADHD portfolio includes Intuniv (guanfacine), approved in the US 2009, and Adderall XR (dextroamphetamine and amphetamine), which has been licensed in the country since 2001.

  • Shire's Q3 net profit doubles

    Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

  • Shire ADHD scholarship programme

    use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

  • New use cleared for Shire ADHD drug

    The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics